Hunan Fangsheng Pharm Co Ltd (603998) - Total Assets
Based on the latest financial reports, Hunan Fangsheng Pharm Co Ltd (603998) holds total assets worth CN¥3.06 Billion CNY (≈ $447.12 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 603998 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Hunan Fangsheng Pharm Co Ltd - Total Assets Trend (2011–2025)
This chart illustrates how Hunan Fangsheng Pharm Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Hunan Fangsheng Pharm Co Ltd to see how much of total assets are deployed in long-term investments.
Hunan Fangsheng Pharm Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Hunan Fangsheng Pharm Co Ltd's total assets of CN¥3.06 Billion consist of 33.2% current assets and 66.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.0% |
| Accounts Receivable | CN¥249.03 Million | 8.2% |
| Inventory | CN¥338.71 Million | 11.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥251.13 Million | 8.2% |
| Goodwill | CN¥265.21 Million | 8.7% |
Asset Composition Trend (2011–2025)
This chart illustrates how Hunan Fangsheng Pharm Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Hunan Fangsheng Pharm Co Ltd market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hunan Fangsheng Pharm Co Ltd's current assets represent 33.2% of total assets in 2025, a decrease from 52.7% in 2011.
- Cash Position: Cash and equivalents constituted 9.0% of total assets in 2025, down from 24.5% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, a decrease from 18.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 11.1% of total assets.
Hunan Fangsheng Pharm Co Ltd Competitors by Total Assets
Key competitors of Hunan Fangsheng Pharm Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.25 Billion |
|
Eris Lifesciences Limited
NSE:ERIS
|
India | Rs71.60 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Lotus Pharmaceutical Co Ltd
TW:1795
|
Taiwan | NT$106.15 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC
|
India | Rs3.22 Billion |
Hunan Fangsheng Pharm Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.90 | 0.83 | 0.88 |
| Quick Ratio | 0.59 | 0.51 | 0.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥-106.97 Million | CN¥-207.30 Million | CN¥-122.45 Million |
Hunan Fangsheng Pharm Co Ltd - Advanced Valuation Insights
This section examines the relationship between Hunan Fangsheng Pharm Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.45 |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | -6.5% |
| Total Assets | CN¥3.06 Billion |
| Market Capitalization | $600.75 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hunan Fangsheng Pharm Co Ltd's assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Hunan Fangsheng Pharm Co Ltd's assets decreased by 6.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Hunan Fangsheng Pharm Co Ltd (2011–2025)
The table below shows the annual total assets of Hunan Fangsheng Pharm Co Ltd from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.06 Billion ≈ $447.16 Million |
-6.45% |
| 2024-12-31 | CN¥3.27 Billion ≈ $478.00 Million |
+6.02% |
| 2023-12-31 | CN¥3.08 Billion ≈ $450.85 Million |
+5.44% |
| 2022-12-31 | CN¥2.92 Billion ≈ $427.60 Million |
+8.05% |
| 2021-12-31 | CN¥2.70 Billion ≈ $395.75 Million |
+20.59% |
| 2020-12-31 | CN¥2.24 Billion ≈ $328.19 Million |
+12.42% |
| 2019-12-31 | CN¥1.99 Billion ≈ $291.92 Million |
+21.45% |
| 2018-12-31 | CN¥1.64 Billion ≈ $240.37 Million |
+19.65% |
| 2017-12-31 | CN¥1.37 Billion ≈ $200.90 Million |
+8.02% |
| 2016-12-31 | CN¥1.27 Billion ≈ $185.99 Million |
+19.16% |
| 2015-12-31 | CN¥1.07 Billion ≈ $156.09 Million |
+14.89% |
| 2014-12-31 | CN¥928.43 Million ≈ $135.86 Million |
+99.09% |
| 2013-12-31 | CN¥466.34 Million ≈ $68.24 Million |
+24.09% |
| 2012-12-31 | CN¥375.81 Million ≈ $54.99 Million |
+14.79% |
| 2011-12-31 | CN¥327.38 Million ≈ $47.91 Million |
-- |
About Hunan Fangsheng Pharm Co Ltd
Hunan Fangsheng Pharmaceutical Co., Ltd. engages in research, develops, produces, and sells traditional Chinese medicine industry and chemical pharmaceutical products in China. The company offers pharmaceutical manufacturing; and provides cardiovascular and cerebrovascular drugs, skeletal muscle system drugs, orthopedic drugs, respiratory drugs, pediatric drugs, gynecological drugs, and anti-infe… Read more